Human Embryonic Stem Cells Could Help to Treat Deafness
News Sep 20, 2012
In research funded by the Medical Research Council and leading UK research charity, Action on Hearing Loss, experts from the University’s Department of Biomedical Sciences developed a method to turn human embryonic stem cells into ear cells.
They then transplanted them into deaf gerbils, obtaining a functional recovery that, on average, was of around 46 per cent. The improvement was evident about four weeks after administering the cells.
As well as proving that stem cells can be used to repair damaged hearing, it is hoped the breakthrough - published in the journal Nature - will lead to new treatments and therapies in the future.
The model of hearing loss successfully treated by the scientists is similar to a human condition known as auditory neuropathy, a form of deafness in which the damage occurs at the level of the cochlear nerve. It is thought to represent up to 15 per cent of the population across the world with profound hearing loss.
Dr Marcelo Rivolta, who led the project, said: “We developed a method to drive human embryonic stem cells to produce both hair cells and neurons, or nerve cells, but we only transplanted the neurons. We then used a technique called auditory brainstem evoked responses (ABR), which measures if the brain can perceive an electrical signal after sound stimulation. The responses of the treated animals were substantially better than those untreated, although the range of improvement was broad. Some subjects did very well, while in others recovery was poor.”
Auditory neuropathy is a type of deafness where the problem lies, not primarily with the hair cells, but in the connection of the hair cells with the brain.
Patients can be born with it and there are cases due to a genetic defect where a few responsible genes have already been identified.
However, there is increasing evidence that environmental factors, such as jaundice at birth and noise exposure later in life, play an important role, at least as risk factors.
Dr Rivolta added: “We believe this an important step forward. We have now a method to produce human cochlear sensory cells that we could use to develop new drugs and treatments, and to study the function of genes. And more importantly, we have the proof-of-concept that human stem cells could be used to repair the damaged ear.
“More research is needed. For instance, we want to understand the long term implications of this treatment and its safety. Moreover, while in auditory neuropathy patients that retain their hair cells the sole application of stem cells could be beneficial; those with more comprehensive damage may need a cochlear implant to compensate for the hair cell deficit. In these patients it is possible that stem cells should be administered in combination with a cochlear implant. It is therefore important to explore this interaction.”
Dr Ralph Holme, Head of Biomedical Research for Action on Hearing Loss, said: “The research we have funded at the University of Sheffield is tremendously encouraging and gives us real hope that it will be possible to fix the actual cause of some types of hearing loss in the future. For the millions of people for whom hearing loss is eroding their quality of life, this can’t come soon enough.”
Dr Paul Colville-Nash, Programme Manager for stem cell, developmental biology and regenerative medicine at the Medical Research Council, which co-funded the research, added: “This is promising research that demonstrates further proof-of-concept that stem cells have the potential to treat a range of human diseases that currently have no effective cures. While any new treatment is likely to take years to reach the clinic, this study clearly demonstrates that investment in UK stem cell research and regenerative medicine is beginning to bear fruit, and that is very exciting.”
Watching Stem Cells Repair Spinal Cord in Real TimeNews
Clues to the reversal of brain and spine injury.READ MORE
Cell Technology Used to Treat Osteochondral Knee DefectNews
Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.READ MORE